The Barth Syndrome Foundation’s (BSF) international Scientific and Medical Advisory Board is a dedicated team of researchers and physicians who generously donate their time and expertise to our mission. Without them, we would not be able to review grant applications with multi-dimensional expertise or write medically-approved educational materials about Barth syndrome. These eminent scientists and physicians are central to our goals and our operation. BSF is incredibly pleased to introduce our members, each of whom has agreed to serve for a four-year term. This international group forms the review panel for research grants and provides scientific and medical advice and guidance to BSF's Board of Directors.
Kathryn Chatfield, MD PhD
Associate Professor of Pediatrics and Director, Cardiac Genetics Clinic, University of Colorado Anschutz
Dr. Kathryn Chatfield is an Associate Professor of Pediatrics in the Division of Cardiology at the University of Colorado School of Medicine and the Director of the Cardiac Genetics Clinic at Children's Hospital Colorado. She holds both an MD and PhD from Dartmouth and completed her Pediatric Cardiology fellowship at the University of Colorado Anschutz Medical Campus. Her clinical expertise spans inherited and metabolic forms of cardiomyopathy, and her research is focused on the role of mitochondrial energy metabolism in pediatric heart disease.
Dr. Chatfield has been a dedicated contributor to the Barth syndrome field for over a decade, with multiple peer-reviewed publications on the disease including work distinguishing the unique metabolic features of Barth syndrome from other forms of pediatric cardiomyopathy. She played an integral role in the TAZPOWER clinical trial — the landmark study of elamipretide in Barth syndrome that ultimately supported the first-ever FDA approval of a treatment for this disease. Her dual training as both a cardiologist and a clinical geneticist positions her uniquely to understand and address the complex, multi-system challenges faced by individuals living with Barth syndrome.
Dr. Chatfield will bring to the Scientific and Medical Advisory Board deep expertise in inherited cardiomyopathy, mitochondrial disease, and rare disease clinical trial development, along with the invaluable perspective of a clinician who cares for Barth syndrome patients in her practice.
